Mandate

Vinge has advised SBB and Sveafastigheter in connection with an exchange offer

July 09, 2024 Banking and Finance

Vinge has advised Samhällsbyggnadsbolaget i Norden AB (SBB) and Sveafastigheter AB in connection with an exchange offer directed to investors in SBB’s outstanding bonds, whereby investors exchanged senior and hybrid bonds in SBB for new senior bonds issued in Sveafastigheter AB. The existing bonds were partly issued under SBB’s EMTN programme, partly on a standalone basis. Following the transaction, the investors have been slotted in under Swedish bond terms on a standalone basis.

As a result of the transaction, outstanding bonds in SBB in aggregate amounts of EUR 275,039,000, SEK 721,000,000 and NOK 40,000,000 were exchanged for new bonds in Sveafastigheter amounting to EUR 110,900,000 (under a framework of EUR 183,500,000) and SEK 412,500,000. In addition to the instrument exchange, SBB also offered, under certain conditions, a cash component as compensation for the exchange.

Danske Bank A/S, DNB Markets, part of DNB Bank ASA, Sweden branch and Skandinaviska Enskilda Banken AB (publ) acted as dealer managers in connection with the exchange offer.

Vinge's team consisted of Mikael Ståhl, Rikard Lindahl, Lionardo Ojeda, William Kåge, Benjamin Vafaeian, August Ahlin and Filip Magnusson.

Related

Vinge advises OsteoCentric on the public offer for Integrum

OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025